Investigation of Dexmedetomidine and Haloperidol in Delirium symptoms in Intensive Care Unit patients.

Phase 1

Recruiting

• Conditions: delirium.; Delirium due to known physiological condition

• Registration Number: IRCT20221128056654N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-05-01

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

Patients who are diagnosed with delirium based on DSM5 criteria.
Patients who have not received non-pharmacological treatments to control symptoms.
5=ICDSC ? RASS=+1
Not being intubated or extubated for more than 24 hours
Hospitalization in ICU for non-surgical reasons

Exclusion Criteria

Patients who receive drugs other than dexmedetomidine or haloperidol for the treatment of delirium (such as other antipsychotics and midazolam)
Receiving dexmedetomidine or haloperidol within 72 hours before entering the study
Patients with a history of drug sensitivity to dexmedetomidine or haloperidol.
Patients with a history of long QTc (<500 ms)
Patients with dementia, Parkinson's, malignant neuroleptic syndrome, patients with a history of major psychiatric disorders such as bipolar and schizophrenia, addiction to various drugs and stimulants.
Women during breastfeeding and pregnancy
Unwillingness of the patient or family to participate in the study
Severe forms of vision and hearing

Study & Design

• Study Type: interventional
• Study Design: Not specified